| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 5
| Issue : 4 | Page : 451-457 |
|
|
Identification of molecular signatures and pathways to identify novel therapeutic targets in mild cognitive impairment: Insights from a systems biomedicine perspective
Vineeta Singh, Vijaya Nath Mishra
Department of Neurology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
Correspondence Address:
Vijaya Nath Mishra
Department of Neurology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/bbrj.bbrj_180_21
|
|
|
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. However, there are no peripheral biomarkers available that can detect AD onset. Mild cognitive impairment (MCI) is the earlier stage of AD. Aims and Objectives: This study aimed to identify the molecular signatures and target and its therapeutic intervention in MCI-AD through a detailed analysis of gene of MCI and AD. Materials and Methods: We used the disease gene set of AD and MCI (GSE4226 and GSE4229) comparing to identify common genes among them. GIn the present study we have attempted to identify gene set, protein-protein interaction and Transcription factors associated with MCI and AD. Result and Conclusion: Conclusively, the present study will provide a set of markers as biological processes, cellular components, molecular function, various pathways, and different TFs which might help in better understanding of disease mechanism progression and also might act as a target for therapeutic interventions for the treatment of MCI and AD.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
